Literature DB >> 2464346

Inhibition of protein synthesis reduces the cytotoxicity of 4'-(9-acridinylamino)methanesulfon-m-anisidide without affecting DNA breakage and DNA topoisomerase II in a murine mastocytoma cell line.

E Schneider1, P A Lawson, R K Ralph.   

Abstract

Stimulation of cleavable complex formation by 4'-(9-acridinylamino)methanesulfon-m-anisidide (mAMSA) and related anticancer drugs is an important initial event in drug action which correlates with cytotoxicity. However, it was recently suggested that factors in addition to cleavable complex formation are needed to express lethality. Therefore we investigated the effects of inhibitors of DNA replication and RNA and protein synthesis on mAMSA-induced cell killing in the K21 subline of the P815 murine mastocytoma cell line. This showed that RNA and protein synthesis, but not DNA replication, was necessary for maximal mAMSA cytotoxicity. Moreover, inhibition of RNA synthesis with cordycepin or protein synthesis with cycloheximide protected cells from the cytotoxic action of mAMSA without reducing DNA breakage or cleavable complex formation and there was no decrease in DNA topoisomerase II activity in nuclear extracts from cells treated with cordycepin or cycloheximide. We conclude that cleavable complex formation is independent of RNA and/or protein synthesis and we propose that the subsequent conversion into a lethal event requires an additional labile protein factor.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2464346     DOI: 10.1016/0006-2952(89)90036-1

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  12 in total

1.  An antitumor drug-induced topoisomerase cleavage complex blocks a bacteriophage T4 replication fork in vivo.

Authors:  G Hong; K N Kreuzer
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

2.  Suppression of sodium arsenite-potentiated cytotoxicity of ultraviolet light by cycloheximide in Chinese hamster ovary cells.

Authors:  T C Lee; S L Kao; L H Yih
Journal:  Arch Toxicol       Date:  1991       Impact factor: 5.153

3.  Thermodynamics of the interactions of m-AMSA and o-AMSA with nucleic acids: influence of ionic strength and DNA base composition.

Authors:  R M Wadkins; D E Graves
Journal:  Nucleic Acids Res       Date:  1989-12-11       Impact factor: 16.971

Review 4.  DNA topoisomerase I and II in cancer chemotherapy: update and perspectives.

Authors:  Y Pommier
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 5.  Defining functional drug-interaction domains on topoisomerase II by exploiting mechanistic differences between drug classes.

Authors:  N Osheroff; A H Corbett; S H Elsea; M Westergaard
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

6.  Characterization of the ATPase activity of topoisomerase II from Leishmania donovani and identification of residues conferring resistance to etoposide.

Authors:  Tanushri Sengupta; Mandira Mukherjee; Aditi Das; Chhabinath Mandal; Rakhee Das; Tanmoy Mukherjee; Hemanta K Majumder
Journal:  Biochem J       Date:  2005-09-01       Impact factor: 3.857

7.  Inhibition of human topoisomerase II by anti-neoplastic benzazolo[3,2-alpha]quinolinium chlorides.

Authors:  P E Vivas-Mejía; O Cox; F A González
Journal:  Mol Cell Biochem       Date:  1998-01       Impact factor: 3.396

8.  Potentiation of etoposide-induced cytotoxicity and DNA damage in CCRF-CEM cells by pretreatment with non-cytotoxic concentrations of arabinosyl cytosine.

Authors:  C M Chresta; R Hicks; J A Hartley; R L Souhami
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 9.  Multilevel therapeutic targeting by topoisomerase inhibitors.

Authors:  P J Smith; S Souès
Journal:  Br J Cancer Suppl       Date:  1994-09

10.  Cell killing and DNA damage by etoposide in Chinese hamster V79 monolayers and spheroids: influence of growth kinetics, growth environment and DNA packaging.

Authors:  P L Olive; J P Banáth; H H Evans
Journal:  Br J Cancer       Date:  1993-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.